Financial Architects, Inc Aurinia Pharmaceuticals Inc. Transaction History

Financial Architects, Inc

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$6.05 - $6.75 $9,075 - $10,125	-1,500 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$6.06 - $7.64 $9,090 - $11,460	1,500 New	1,500 $10,000
Q1 2019 May 03, 2019	SELL	$6.06 - $7.64 $12,120 - $15,280	-2,000 Closed	0 $0
Q4 2017 Feb 12, 2018	SELL	$4.53 - $7.09 $3,624 - $5,672	-800 Reduced 28.57%	2,000 $9,000
Q3 2017 Nov 01, 2017	BUY	$5.71 - $6.9 $15,988 - $19,320	2,800	2,800 $18,000

208

58.6M

1.14M

1.51M

Ticker AUPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 141,892,000
Market Cap $1.24B
Description
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license...

Get notified when there are updates to the investment portfolio of Financial Architects, Inc, based on Form 13F filings with the SEC.

Stay updated on Financial Architects, Inc with notifications on news.